Inhibition Of PI3K/mTOR Overcomes Nilotinib Resistance In BCR-ABL1 Positive Leukemia Cells

被引：0
|
作者：
Ding, Jie
Romani, Julia
Zaborski, Margarete
MacLeod, Roderick A. F.
Nagel, Stefan
Drexler, Hans G.
Quentmeier, Hilmar
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.4906.4906
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4906
引用
收藏
页数：1
相关论文
共 50 条
  • [1] INHIBITION OF PI3K/MTOR OVERCOMES NILOTINIB RESISTANCE IN BCR-ABL1 POSITIVE LEUKEMIA CELLS
    Ding, J.
    Romani, J.
    Zaborski, M.
    Nagel, S.
    Drexler, H.
    Quentmeier, H.
    HAEMATOLOGICA, 2013, 98 : 402 - 403
  • [2] Inhibition of PI3K/mTOR Overcomes Nilotinib Resistance in BCR-ABL1 Positive Leukemia Cells through Translational Down-Regulation of MDM2
    Ding, Jie
    Romani, Julia
    Zaborski, Margarete
    MacLeod, Roderick A. F.
    Nagel, Stefan
    Drexler, Hans G.
    Quentmeier, Hilmar
    PLOS ONE, 2013, 8 (12):
  • [3] Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
    Kharas, Michael G.
    Janes, Matthew R.
    Scarfone, Vanessa M.
    Lilly, Michael B.
    Knight, Zachary A.
    Shokat, Kevan M.
    Fruman, David A.
    JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (09): : 3038 - 3050
  • [4] The Efficacy of Dual PI3K and mTOR Inhibitor, NVP-BEZ235 against BCR-ABL Positive Leukemia Cells Include ABL Kinase Domain Mutation in Combination with Nilotinib
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Kimura, Shinya
    Maekawa, Taira
    Ohyashiki, Kazuma
    BLOOD, 2009, 114 (22) : 1455 - 1455
  • [5] Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Tanaka, Yuko
    Kitahara, Toshihiko
    Kimura, Shinya
    Maekawa, Taira
    Ohyashiki, Kazuma
    CANCER BIOLOGY & THERAPY, 2014, 15 (02) : 207 - 215
  • [6] Inhibition of the PI3K/AKT/mTOR pathway overcomes resistance to ABL-directed TKI in long-term cultured acute lymphoblastic leukemia (ALL) cells
    Badura, S.
    Tesanovic, T.
    Pfeifer, H.
    Hohnloser, C.
    Serve, H.
    Ruthardt, M.
    Ottmann, O. G.
    ONKOLOGIE, 2011, 34 : 207 - 207
  • [7] Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells (vol 118, pg 3038, 2008)
    Kharas, Michael G.
    Janes, Matthew R.
    Scarfone, Vanessa M.
    Lilly, Michael B.
    Knight, Zachary A.
    Shokat, Kevan M.
    Fruman, David A.
    JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (06): : 2438 - 2438
  • [8] EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway
    Huang, Rui
    Liu, Huimin
    Chen, Yiran
    He, Yanjie
    Kang, Qian
    Tu, Sanfang
    He, Yingzhi
    Zhou, Xuan
    Wang, Lei
    Yang, Jilong
    Wu, Anqin
    Li, Yuhua
    ONCOLOGY REPORTS, 2018, 39 (01) : 119 - 128
  • [9] PARP Inhibition Sensitize BCR-ABL1 Positive Cel
    Hiroki, Haruka
    Takagi, Masatoshi
    Ishi, Yuko
    Piao, Jinhua
    Morio, Tomohiro
    BLOOD, 2019, 134
  • [10] PARP Inhibition Sensitize BCR-ABL1 Positive Cell
    Hiroki, Haruka
    Ishii, Yuko
    Piao, Jinhua
    Morio, Tomohiro
    Takagi, Masatoshi
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S12 - S12
12345